We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.1B
1-Year Est. Return
57.92%
This Fund
S&P 500
This Quarter
Est. Return
+25.19%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$4.52B
AUM Growth
+$762M
(+20%)
Cap. Flow
+$251M
Cap. Flow
% of AUM
5.54%
Top 10 Holdings %
Top 10 Hldgs %
32.69%
Holding
126
New
33
Increased
18
Reduced
34
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stryker
SYK
|
+$104M |
| 2 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$86M |
| 3 |
AGN
Allergan plc
AGN
|
+$83.3M |
| 4 |
Pfizer
PFE
|
+$80.2M |
| 5 |
Puma Biotechnology
PBYI
|
+$79.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$145M |
| 2 |
Abbott
ABT
|
+$82.8M |
| 3 |
GoDaddy
GDDY
|
+$79.9M |
| 4 |
AERI
Aerie Pharmaceuticals
AERI
|
+$68.4M |
| 5 |
Blackrock
BLK
|
+$65.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.61% |
| 2 | Technology | 11.18% |
| 3 | Communication Services | 3.96% |
| 4 | Consumer Discretionary | 3.1% |
| 5 | Financials | 1.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
76
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.81M | 0.19% |
+120,166
| New | +$8.17M |
|
77
Accuray
ARAY
$32.2M
| $7.71M | 0.17% |
1,617,297
-1,129,339
| -41% | -$5.14M |
|
|
APTX
78
DELISTED
Aptinyx Inc. Common Stock
APTX
| $7.27M | 0.16% |
1,795,149
-56,983
| -3% | -$413K |
|
79
Lyft
LYFT
$6.22B
| $6.9M | 0.15% |
+88,182
| New | +$6.9M |
|
|
SNNA
80
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
| $6.23M | 0.14% |
2,684,678
+1,108,059
| +70% | +$3M |
|
|
GRTS
81
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $4.98M | 0.11% |
374,656
-630,957
| -63% | -$8.43M |
|
82
Zai Lab
ZLAB
$2.05B
| $4.65M | 0.1% |
+157,442
| New | +$4.31M |
|
83
Shopify
SHOP
$152B
| $4.05M | 0.09% |
+196,160
| New | +$3.46M |
|
|
NTGN
84
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
| $2.73M | 0.06% |
422,396
-556,606
| -57% | -$2.91M |
|
|
UBX
85
DELISTED
Unity Biotechnology
UBX
| $1.1M | 0.02% |
13,519
-69,483
| -84% | -$7.88M |
|
|
86
Abbott
ABT
$185B
| – | – |
-1,144,699
| Closed | -$82.8M |
|
87
Adobe
ADBE
$99.9B
| – | – |
-1,071
| Closed | -$242K |
|
|
ALLK
88
DELISTED
Allakos
ALLK
| – | – |
-618,284
| Closed | -$30.2M |
|
89
Allogene Therapeutics
ALLO
$635M
| – | – |
-617,193
| Closed | -$16.6M |
|
90
AnaptysBio
ANAB
$1.59B
| – | – |
-605,345
| Closed | -$38.6M |
|
91
argenx
ARGX
$52B
| – | – |
-117,834
| Closed | -$11.3M |
|
92
Ascendis Pharma A/S
ASND
$16B
| – | – |
-27,519
| Closed | -$1.72M |
|
|
93
Blackrock
BLK
$175B
| – | – |
-166,775
| Closed | -$65.5M |
|
94
CALL
Cigna
CI
$74.5B
| – | – |
-554,300
| Closed | -$105M |
|
|
95
Cigna
CI
$74.5B
| – | – |
-202,399
| Closed | -$38.4M |
|
96
CME Group
CME
$95.7B
| – | – |
-219,204
| Closed | -$41.2M |
|
|
DOCU
97
DocuSign
DOCU
$10.5B
| – | – |
-19,199
| Closed | -$769K |
|
98
DaVita
DVA
$15B
| – | – |
-962,234
| Closed | -$49.5M |
|
99
Elastic
ESTC
$7.15B
| – | – |
-72,151
| Closed | -$5.16M |
|
100
Liberty Media Series C
FWONK
$24.5B
| – | – |
-15,043
| Closed | -$447K |
|
Similar funds
DAM
MAM
LCM
DAM
KCM
CF
MIA
YL
PFM Health Sciences's Q1 2019 Portfolio in Review
As of Q1 2019, PFM Health Sciences held 126 positions worth $4.52B, up 20% from $3.76B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
PFM Health Sciences deployed $251M of net new capital in Q1 2019, opening 33 new positions and adding to 18 existing holdings. Its largest new stake was Stryker: 579,444 shares worth $114M.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 51% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Spark Therapeutics, Inc. Common Stock, an estimated $145M trimmed.
- PFM Health Sciences's largest Q1 2019 buy was Stryker: 579,444 shares worth $114M.
- PFM Health Sciences added most to Pfizer in Q1 2019, an estimated $80.2M increase.
- PFM Health Sciences's biggest Q1 2019 reduction was Spark Therapeutics, Inc. Common Stock, cutting an estimated $145M.
- PFM Health Sciences fully exited Abbott in Q1 2019, selling an estimated $82.8M.
- PFM Health Sciences's ten largest holdings make up 33% of its $4.52B portfolio in Q1 2019.
- PFM Health Sciences opened 33 new positions and closed 36 in Q1 2019.
- PFM Health Sciences's portfolio value rose 20% quarter-over-quarter to $4.52B.
Based on PFM Health Sciences's 13F filing for Q1 2019, filed 15 May 2019.